Literature DB >> 16118448

Isolation and culture of hepatic stellate cells.

Ralf Weiskirchen1, Axel M Gressner.   

Abstract

Hepatic stellate cells (HSCs) are routinely prepared by collagenase/pronase digestion of liver using a perfusion system and subsequent fractionation of the heterogeneous cell suspension on continuous density gradients made out of Nycodenz, metrizamide, stractan, or percoll. Because of their lipid content, stellate cells are the least dense fraction of the nonparenchymal cells, and during centrifugation they float effectively away from other hepatic cells resulting in preparations containing almost 80% stellate cells. The degree of purity can be increased by further enrichment of cells by methods like centrifugal elutriation or Scatter-activated cell sorting. We present a detailed protocol from our laboratory to obtain a high number of pure, viable, freshly isolated hepatic stellate cells from rat liver. This two-step protocol (collagenase/pronase digestion and Nycodenz gradient) yields a preparation of approx 4-5 x 107 cells enriched in 74% HSC having a viability of at least 76% as estimated by Trypan blue exclusion test. Further purification by centrifugal elutriation results in virtually pure HSC preparations ( >98%).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118448     DOI: 10.1385/1-59259-940-0:099

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  65 in total

1.  miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis.

Authors:  Chuan-Feng Huang; Cheng-Chao Sun; Fang Zhao; Ya-Dong Zhang; De-Jia Li
Journal:  J Gastroenterol       Date:  2014-08-26       Impact factor: 7.527

2.  Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice.

Authors:  Marie-Luise Berres; Rory R Koenen; Anna Rueland; Mirko Moreno Zaldivar; Daniel Heinrichs; Hacer Sahin; Petra Schmitz; Konrad L Streetz; Thomas Berg; Nikolaus Gassler; Ralf Weiskirchen; Amanda Proudfoot; Christian Weber; Christian Trautwein; Hermann E Wasmuth
Journal:  J Clin Invest       Date:  2010-10-18       Impact factor: 14.808

3.  RNA-binding protein RBMS3 is expressed in activated hepatic stellate cells and liver fibrosis and increases expression of transcription factor Prx1.

Authors:  Dillon Fritz; Branko Stefanovic
Journal:  J Mol Biol       Date:  2007-06-09       Impact factor: 5.469

4.  Isolation of human hepatocytes by a two-step collagenase perfusion procedure.

Authors:  Serene M L Lee; Celine Schelcher; Maresa Demmel; Maria Hauner; Wolfgang E Thasler
Journal:  J Vis Exp       Date:  2013-09-03       Impact factor: 1.355

5.  miRNA studies in in vitro and in vivo activated hepatic stellate cells.

Authors:  Gunter Maubach; Michelle Chin Chia Lim; Jinmiao Chen; Henry Yang; Lang Zhuo
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

6.  An Elf2-like transcription factor acts as repressor of the mouse ecto-5'-nucleotidase gene expression in hepatic myofibroblasts.

Authors:  Michel Fausther; Elise G Lavoie; Jessica R Goree; Jonathan A Dranoff
Journal:  Purinergic Signal       Date:  2017-06-30       Impact factor: 3.765

7.  Versican: a novel modulator of hepatic fibrosis.

Authors:  Terence N Bukong; Sean B Maurice; Barinder Chahal; David F Schaeffer; Paul J Winwood
Journal:  Lab Invest       Date:  2016-01-11       Impact factor: 5.662

8.  CCN1 induces hepatic ductular reaction through integrin αvβ₅-mediated activation of NF-κB.

Authors:  Ki-Hyun Kim; Chih-Chiun Chen; Gianfranco Alpini; Lester F Lau
Journal:  J Clin Invest       Date:  2015-03-30       Impact factor: 14.808

9.  Nuclear cathepsin F regulates activation markers in rat hepatic stellate cells.

Authors:  Gunter Maubach; Michelle Chin Chia Lim; Lang Zhuo
Journal:  Mol Biol Cell       Date:  2008-07-30       Impact factor: 4.138

10.  Interleukin-27 acts on hepatic stellate cells and induces signal transducer and activator of transcription 1-dependent responses.

Authors:  Caroline Schoenherr; Ralf Weiskirchen; Serge Haan
Journal:  Cell Commun Signal       Date:  2010-08-19       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.